P53 and CD34 Immunohistochemical Expression on Bone Marrow Biopsy As Predictive Marker of Response to Erythropoietin in Low Risk Myelodysplastic Syndrome

P53 and CD34 Immunohistochemical Expression on Bone Marrow Biopsy As Predictive Marker of Response to Erythropoietin in Low Risk Myelodysplastic Syndrome

Introduction: Erythropoietin stimulating agents (ESAs) are first-line therapy for International Prognostic Scoring System (IPSS)-low risk myelodysplastic syndrome (MDS) when symptomatic anaemia (Hb

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2018-11, Vol.132 (Supplement 1), p.5511-5511
Hauptverfasser: Reda, Gianluigi, Boggio, Francesca, Cassin, Ramona, Riva, Marta, Barella, Marco, del Gobbo, Alessandro, Bandiera, Laura, Bonoldi, Emanuela, Molteni, Alfredo, Cortelezzi, Agostino, Gianelli, Umberto
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction: Erythropoietin stimulating agents (ESAs) are first-line therapy for International Prognostic Scoring System (IPSS)-low risk myelodysplastic syndrome (MDS) when symptomatic anaemia (Hb
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2018-99-118811